A Multicenter, Single-arm, Open Label Treatment Protocol to Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
The purpose of this treatment protocol is to provide expanded access to MDV3100 and monitor its safety in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- drug : MDV3100
Ages Eligible For Study:
- Histologically or cytologically confirmed adenocarcinoma of the prostate - Ongoing androgen deprivation therapy with a gonadotropin-releasing hormone (GnRH) analogue (agonist or antagonist) or orchiectomy - At least one prior chemotherapy regimen for metastatic castration-resistant prostate cancer with at least one regimen containing docetaxel - Progressive disease as evidenced by prostate specific antigen (PSA) rise or radiographic or clinical worsening of disease - No known or suspected brain metastasis - There is no comparable or satisfactory alternative therapy to treat the subject's disease - Eastern Cooperative Oncology Group (ECOG) performance status of 0-2